ZA867464B - Pharmaceutical composition of the type which undergoes liquid-gel phase transition - Google Patents

Pharmaceutical composition of the type which undergoes liquid-gel phase transition

Info

Publication number
ZA867464B
ZA867464B ZA867464A ZA867464A ZA867464B ZA 867464 B ZA867464 B ZA 867464B ZA 867464 A ZA867464 A ZA 867464A ZA 867464 A ZA867464 A ZA 867464A ZA 867464 B ZA867464 B ZA 867464B
Authority
ZA
South Africa
Prior art keywords
type
pharmaceutical composition
phase transition
gel phase
liquid
Prior art date
Application number
ZA867464A
Other languages
English (en)
Inventor
Claude Mazuel
Marie-Claire Friteyere
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of ZA867464B publication Critical patent/ZA867464B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/04—Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Inorganic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ZA867464A 1985-10-03 1986-09-30 Pharmaceutical composition of the type which undergoes liquid-gel phase transition ZA867464B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR8514689A FR2588189B1 (fr) 1985-10-03 1985-10-03 Composition pharmaceutique de type a transition de phase liquide-gel

Publications (1)

Publication Number Publication Date
ZA867464B true ZA867464B (en) 1987-07-29

Family

ID=9323509

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA867464A ZA867464B (en) 1985-10-03 1986-09-30 Pharmaceutical composition of the type which undergoes liquid-gel phase transition

Country Status (25)

Country Link
US (1) US4861760A (fr)
EP (1) EP0227494B1 (fr)
JP (1) JPH0667853B2 (fr)
KR (1) KR940000229B1 (fr)
CN (1) CN1046094C (fr)
AT (1) ATE72990T1 (fr)
AU (1) AU595240B2 (fr)
CA (1) CA1280367C (fr)
CY (1) CY1779A (fr)
DE (2) DE227494T1 (fr)
DK (1) DK170500B1 (fr)
ES (1) ES2002401A6 (fr)
FI (1) FI91217C (fr)
FR (1) FR2588189B1 (fr)
GR (1) GR862444B (fr)
HK (1) HK42594A (fr)
IE (1) IE59464B1 (fr)
IL (1) IL80156A (fr)
LU (1) LU88694I2 (fr)
LV (1) LV5725B4 (fr)
NL (1) NL950012I1 (fr)
NO (2) NO173212C (fr)
NZ (1) NZ217662A (fr)
PT (1) PT83471B (fr)
ZA (1) ZA867464B (fr)

Families Citing this family (361)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5095026A (en) * 1983-02-04 1992-03-10 University Of Iowa Research Foundation Prodrugs of carbonic anhydrase inhibitors
US5200180A (en) * 1987-06-26 1993-04-06 Christian Bannert Pharmaceutical composition for the treatment of the human eye
FR2618333B1 (fr) * 1987-07-20 1990-07-13 Merck Sharp & Dohme Composition pharmaceutique et/ou cosmetique a usage topique contenant de la gomme rhamsam
US5843156A (en) * 1988-08-24 1998-12-01 Endoluminal Therapeutics, Inc. Local polymeric gel cellular therapy
US6436425B1 (en) 1988-11-16 2002-08-20 Mdv Technologies, Inc. Method and non-gelling composition for inhibiting post-surgical adhesions
US4911926A (en) * 1988-11-16 1990-03-27 Mediventures Inc. Method and composition for reducing postsurgical adhesions
US5034406A (en) * 1989-09-26 1991-07-23 Allergan, Inc. Method for reducing or maintaining intraocular pressure
US5461081A (en) * 1989-09-28 1995-10-24 Alcon Laboratories, Inc. Topical ophthalmic pharmaceutical vehicles
US5521222A (en) * 1989-09-28 1996-05-28 Alcon Laboratories, Inc. Topical ophthalmic pharmaceutical vehicles
FR2653018A1 (fr) 1989-10-17 1991-04-19 Merck Sharp & Dohme Composition ophtalmique non solide a base de microparticules de polymere contenant au moins un principe actif en suspension dans un milieu dispersant et procede de preparation de ladite composition.
FR2653021A1 (fr) * 1989-10-17 1991-04-19 Merck Sharp & Dohme Composition ophtalmique aqueuse liquide a transition de phase liquide-gel.
US5141928B1 (en) * 1989-12-20 1995-11-14 Brujo Inc Ophthalmic medication
US5496471A (en) * 1990-01-08 1996-03-05 Ciba-Geigy Corporation Apparatus for removing components from solutions
FR2657018A1 (fr) * 1990-01-12 1991-07-19 Merck Sharp & Dohme Composition ophtalmique fluide a base de microparticules lipidiques contenant au moins un principe actif et son procede de preparation.
US5298260A (en) * 1990-05-01 1994-03-29 Mediventures, Inc. Topical drug delivery with polyoxyalkylene polymer thermoreversible gels adjustable for pH and osmolality
US5593683A (en) * 1990-05-01 1997-01-14 Mdv Technologies, Inc. Method of making thermoreversible polyoxyalkylene gels
US5252318A (en) * 1990-06-15 1993-10-12 Allergan, Inc. Reversible gelation compositions and methods of use
CA2044878C (fr) * 1990-08-07 2000-12-26 Tacey X. Viegas Gels thermoreversibles et thermo-irreversibles
US5346703A (en) * 1990-08-07 1994-09-13 Mediventures, Inc. Body cavity drug delivery with thermo-irreversible polyoxyalkylene and ionic polysaccharide gels
FR2665635A1 (fr) * 1990-08-10 1992-02-14 Merck Sharp & Dohme Composition pharmaceutique fluide a base d'un complexe metallique et son procede de preparation.
US5847023A (en) * 1990-10-26 1998-12-08 Mdv Technologies, Inc. Thermal irreversible gel corneal contact lens formed in situ
JP2594486B2 (ja) * 1991-01-15 1997-03-26 アルコン ラボラトリーズ インコーポレイテッド 局所的眼薬組成物
US5212162A (en) * 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
SG84487A1 (en) 1991-04-17 2001-11-20 Merck & Co Inc Ophthalmic compositions comprising combinations of a carbonic anhydrase inhibitor and a b-adrenergic antagonist
ZA927277B (en) * 1991-10-02 1993-05-19 Boston Ocular Res Dry eye treatment process and solution.
US5318780A (en) * 1991-10-30 1994-06-07 Mediventures Inc. Medical uses of in situ formed gels
HU220864B1 (en) * 1993-04-16 2002-06-29 Wakamoto Pharma Co Ltd Reversible, thermally gelling water-base medicinal compositions
SE9301877D0 (sv) * 1993-06-02 1993-06-02 Kabi Pharmacia Ab In situ gel for therapeutic use
US5545617A (en) * 1993-11-12 1996-08-13 The Schepens Eye Research Institute, Inc. Therapeutic regulation of abnormal conjunctival goblet cell mucous secretion
CA2166722A1 (fr) * 1994-05-06 1995-11-16 Manoj L. Maniar Utilisation de derives tocopheryle de vitamine e dans des compositions ophtalmiques
IL114193A (en) * 1994-06-20 2000-02-29 Teva Pharma Ophthalmic pharmaceutical compositions based on sodium alginate
US5585398A (en) * 1994-07-15 1996-12-17 Ernst; Amy A. Topical anesthetic comprising lidocaine, adrenaline, and tetracaine, and its method of use
US6316443B1 (en) 1994-08-04 2001-11-13 Merck & Co., Inc. Ophthalmic compositions comprising combinations of a carbonic anhydrase inhibitor and a β-adrenergic antagonist
US5827835A (en) * 1994-08-30 1998-10-27 Alcon Laboratories, Inc. Thermally-gelling emulsions
ATE208186T1 (de) * 1994-08-30 2001-11-15 Alcon Lab Inc Thermisch gelierende trägerstoffe zur arzneistoffabgabe, die zelluloseether enthalten
US5516808A (en) * 1994-10-27 1996-05-14 Sawaya; Assad S. Topical cellulose pharmaceutical formulation
US5603929A (en) * 1994-11-16 1997-02-18 Alcon Laboratories, Inc. Preserved ophthalmic drug compositions containing polymeric quaternary ammonium compounds
US6165490A (en) * 1996-04-05 2000-12-26 Staar Surgical Ag Biological material, method of preparing such materials, uses thereof and products made therefrom
US6172054B1 (en) 1995-06-15 2001-01-09 Alcon Laboratories, Inc. Combination therapy for lowering and controlling intraocular pressure
US5843470A (en) * 1995-10-06 1998-12-01 Mdv Technologies, Inc. Method and composition for inhibiting post-surgical adhesions
AU704938B2 (en) * 1995-11-17 1999-05-06 Alcon Laboratories, Inc. Combination therapy for treating glaucoma
US6441047B2 (en) 1995-11-17 2002-08-27 Alcon Manufacturing Ltd.. Combination therapy for treating glaucoma
US6610292B2 (en) * 1995-11-22 2003-08-26 Ista Pharmaceuticals, Inc. Use of hyaluronidase in the manufacture of an ophthalmic preparation for liquefying vitreous humor in the treatment of eye disorders
US5866120A (en) 1995-11-22 1999-02-02 Advanced Corneal Systems, Inc. Method for accelerating clearance of hemorrhagic blood from the vitreous humor with hyaluronidase
US5641532A (en) * 1995-12-15 1997-06-24 The Procter & Gamble Company Beverages having stable flavor/cloud emulsions in the presence of polyphosphate-containing preservative systems by including gellan gum
US6245354B1 (en) 1996-02-13 2001-06-12 Dainippon Pharmaceutical Co., Ltd. Drug delivery system using galactoxyloglucan
FR2754712B1 (fr) 1996-10-17 1999-09-03 Merck Sharp Dohme Chibret Lab Compositions ophtalmiques
US5888493A (en) * 1996-12-05 1999-03-30 Sawaya; Assad S. Ophthalmic aqueous gel formulation and related methods
JP2001519787A (ja) * 1997-04-03 2001-10-23 ポイント バイオメディカル コーポレイション 膀胱内ドラッグデリバリーシステム
GB9707934D0 (en) * 1997-04-18 1997-06-04 Danbiosyst Uk Improved delivery of drugs to mucosal surfaces
ES2206965T3 (es) * 1997-07-29 2004-05-16 Alcon Laboratories, Inc. Composiciones oftalmicas que contienen polimeros de galactomanana y borato.
ATE225392T1 (de) * 1997-07-29 2002-10-15 Alcon Lab Inc Konditionierungslösungen für die pflege von harten kontaktlinsen
AU8570498A (en) 1997-07-29 1999-02-22 Alcon Laboratories, Inc. Switchable viscoelastic systems containing galactomannan polymers and borate
US20040063678A1 (en) * 1997-10-06 2004-04-01 Bausch & Lomb Incorporated Dexamethasone Gel
US6174524B1 (en) 1999-03-26 2001-01-16 Alcon Laboratories, Inc. Gelling ophthalmic compositions containing xanthan gum
US6261547B1 (en) 1998-04-07 2001-07-17 Alcon Manufacturing, Ltd. Gelling ophthalmic compositions containing xanthan gum
US6312666B1 (en) * 1998-11-12 2001-11-06 3M Innovative Properties Company Methods of whitening teeth
US6312667B1 (en) * 1998-11-12 2001-11-06 3M Innovative Properties Company Methods of etching hard tissue in the oral environment
US6669927B2 (en) 1998-11-12 2003-12-30 3M Innovative Properties Company Dental compositions
AU770365B2 (en) * 1998-12-11 2004-02-19 Bakulesh Mafatlal Khamar The process for manufacturing formulation of topical beta blockers with improved efficacy
EP1616869B1 (fr) 1999-01-25 2012-04-04 National Jewish Health Prophirines substituees et leur utilisation therapeutique
AU8008300A (en) 1999-11-01 2001-05-14 Alcon Inc. Pharmaceutical compositions containing a fluoroquinolone antibiotic drug and xanthan gum
PE20020146A1 (es) * 2000-07-13 2002-03-31 Upjohn Co Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2)
PT1305033E (pt) 2000-07-28 2005-01-31 Alcon Inc Composicoes farmaceuticas que contem tobramicina e goma de xantano
US20030219461A1 (en) * 2000-09-12 2003-11-27 Britten Nancy J. Parenteral combination therapy for infective conditions
PE20020578A1 (es) 2000-10-10 2002-08-14 Upjohn Co Una composicion de antibiotico topico para el tratamiento de infecciones oculares
JP2002154989A (ja) * 2000-11-14 2002-05-28 Lion Corp 眼科用組成物、及び生体粘膜への薬物の滞留性向上組成物
US7084130B2 (en) * 2001-12-11 2006-08-01 Alcon, Inc. Intraocular irrigating solution having improved flow characteristics
US20090258955A1 (en) * 2000-12-20 2009-10-15 Alcon, Inc. Intraocular irrigating solution having improved flow characteristics
US7169755B2 (en) * 2000-12-20 2007-01-30 Alcon, Inc. Solution for removing cataracts via liquefracture
AU2002232437A1 (en) * 2000-12-20 2002-07-01 Alcon Universal Ltd. Ophthalmic lubricating solution adapted for use in lasik surgery
PT1343474E (pt) * 2000-12-20 2010-04-19 Alcon Inc Solução de irrigação intra-ocular com características de fluidez aperfeiçoadas
AU2002230504A1 (en) * 2000-12-20 2002-07-01 Alcon Universal Ltd. Ophthalmic irrigating solution adapted for use in lasik surgery
US20040121947A1 (en) * 2000-12-28 2004-06-24 Oklahoma Medical Research Foundation Compounds which inhibit beta-secretase activity and methods of use thereof
US20020172712A1 (en) * 2001-03-19 2002-11-21 Alan Drizen Antiemetic, anti-motion sustained release drug delivery system
EP1439842A4 (fr) * 2001-06-01 2009-09-02 Nat Jewish Med & Res Center Capteurs oxydants destines au traitement du diabete ou a etre utilises dans une transplantation ou a induire une tolerance immunitaire
US20030013753A1 (en) * 2001-06-05 2003-01-16 Ronald Aung-Din Transdermal migraine therapy
US8329734B2 (en) * 2009-07-27 2012-12-11 Afgin Pharma Llc Topical therapy for migraine
US20030220376A1 (en) * 2001-08-10 2003-11-27 Pharmacia Corporation Methods for treating carbonic anhydrase mediated disorders
US20080199524A1 (en) * 2001-08-10 2008-08-21 Toray Industries, Inc. Eyedrops containing particulate agar
EP2213308A1 (fr) 2001-08-10 2010-08-04 Toray Industries Inc. Gouttes oculaires contenant agar
US20060234944A1 (en) * 2001-10-23 2006-10-19 Oklahoma Medical Reseach Foundation Beta-secretase inhibitors and methods of use
CA2464736A1 (fr) * 2001-10-23 2003-05-15 Oklahoma Medical Research Foundation Inhibiteurs de la beta-secretase et leurs procede d'utilisation
US6620405B2 (en) 2001-11-01 2003-09-16 3M Innovative Properties Company Delivery of hydrogel compositions as a fine mist
CA2477044A1 (fr) * 2002-02-22 2003-09-04 Pharmacia Corporation Formulation ophtalmique contenant un systeme de gomme
US7666876B2 (en) * 2002-03-19 2010-02-23 Vernalis (R&D) Limited Buprenorphine formulations for intranasal delivery
US7030149B2 (en) 2002-04-19 2006-04-18 Allergan, Inc. Combination of brimonidine timolol for topical ophthalmic use
US7642258B2 (en) * 2002-04-19 2010-01-05 Allergan, Inc. Combination of brimonidine and timolol for topical ophthalmic use
AU2003241398A1 (en) * 2002-05-06 2003-11-17 Washington University Methods of treatment of glaucoma and other conditions mediated by nos-2 expression via inhibition of the egfr pathway
US20080153894A1 (en) * 2002-12-19 2008-06-26 Pharmacia Corporation Cyclooxygenase-2 inhibitor and antibacterial agent combination for intramammary treatment of mastitis
US20060172972A1 (en) * 2002-12-20 2006-08-03 Chakshu Research Inc Formulation and method for administration of ophthalmologically active agents
AU2003297511B2 (en) * 2002-12-20 2010-01-21 Chakshu Research, Inc. Ophthalmic formulation for the prevention and treatment of ocular conditions
US20060177430A1 (en) * 2002-12-20 2006-08-10 Chakshu Research Inc Treatment of ocular disorders with ophthalmic formulations containing methylsulfonylmethane as a transport enhancer
US20060166879A1 (en) * 2002-12-20 2006-07-27 Chakshu Research Inc Treatment of conditions associated with the presence of macromolecular aggregates, particularly ophthalmic disorders
GB0300531D0 (en) 2003-01-10 2003-02-12 West Pharm Serv Drug Res Ltd Pharmaceutical compositions
US20040191332A1 (en) * 2003-03-27 2004-09-30 Allergan, Inc. Preserved ophthalmic compositions
EP1644004A4 (fr) * 2003-06-20 2010-10-06 Ronald Aung-Din Therapie locale pour le traitement des migraines, des claquages musculaires, des spasmes musculaires, de la spasticite et d'etats apparentes
CA2549737A1 (fr) * 2003-11-10 2005-05-26 Toray Industries, Inc. Composition contenant des polysaccharides et solution ophtalmique stabilisant le film lacrymal
EP1696878A1 (fr) * 2003-12-11 2006-09-06 Alcon, Inc. Compositions ophtalmologiques contenant un systeme gelifiant a base de polysaccharide/borate
US20050129770A1 (en) * 2003-12-11 2005-06-16 Alcon, Inc. Ophthalmic compositions containing a PVA/borate gelling system
JP4771044B2 (ja) * 2004-09-15 2011-09-14 大正製薬株式会社 粘膜適用液剤
US20080207527A1 (en) * 2004-09-17 2008-08-28 Comentis, Inc. Bicyclic Compounds Which Inhibit Beta-Secretase Activity and Methods of Use Thereof
EP1799660A2 (fr) * 2004-09-17 2007-06-27 Comentis, Inc. Composes amino inhibant l'activite de la beta-secretase memapsin 2 et methodes d'utilisation
CA2582324A1 (fr) * 2004-10-01 2006-04-13 Merck & Co., Inc. Compositions et methodes de traitement de maladies ophtalmiques
EP1831225A2 (fr) 2004-11-19 2007-09-12 The Regents of the University of California Pyrazolopyrimidines anti-inflammatoires
US20070059274A1 (en) * 2004-12-01 2007-03-15 Bahram Asgharian Ophthalmic compositions containing a PVA/borate gelling system
US7485619B2 (en) * 2005-01-31 2009-02-03 Yeon Sook KIM Antimicrobial agent
KR20080015079A (ko) * 2005-04-08 2008-02-18 코멘티스, 인코포레이티드 베타 세크레타제 활성을 억제하는 화합물 및 이것의 사용방법
AU2006270094A1 (en) * 2005-07-15 2007-01-25 Chakshu Research Inc. Prevention and treatment of ophthalmic complications of diabetes
US7534795B2 (en) * 2005-10-25 2009-05-19 Allergan, Inc. Compounds and their use related to compositions for treating disease
CA2628570A1 (fr) 2005-11-09 2007-05-18 Combinatorx, Incorporated Procedes, compositions et kits pour le traitement de pathologies
AU2006331790A1 (en) * 2005-12-19 2007-07-05 Comentis, Inc. Topical mecamylamine formulations for ocular administration and uses therof
TW200808375A (en) 2006-05-12 2008-02-16 Otsuka Pharma Co Ltd Hydrogel suspension and manufacturing process thereof
KR100802534B1 (ko) 2006-06-13 2008-02-14 주식회사태준제약 저자극성 점안제 조성물 및 이의 제조 방법
CN101541783B (zh) 2006-06-30 2014-10-01 苏尼西斯制药有限公司 吡啶酮基pdk1抑制剂
HUE043228T2 (hu) 2007-06-22 2019-08-28 Univ Texas Stabil szubmikron peptid vagy protein részecskék képzése vékonyfilm fagyasztással
CA2697166A1 (fr) * 2007-07-26 2009-01-29 Comentis, Inc. Composes qui inhibent l'activite de la beta-secretase et procedes d'utilisation de ceux-ci
US8299267B2 (en) * 2007-09-24 2012-10-30 Comentis, Inc. (3-hydroxy-4-amino-butan-2-yl) -3- (2-thiazol-2-yl-pyrrolidine-1-carbonyl) benzamide derivatives and related compounds as beta-secretase inhibitors for treating
WO2009110009A2 (fr) * 2008-03-07 2009-09-11 Sun Pharma Advanced Research Company Ltd., Composition ophtalmique
US11382895B2 (en) 2008-05-23 2022-07-12 National Jewish Health Methods for treating injury associated with exposure to an alkylating species
US8592424B2 (en) 2008-06-30 2013-11-26 Afgin Pharma Llc Topical regional neuro-affective therapy
US20110224223A1 (en) 2008-07-08 2011-09-15 The Regents Of The University Of California, A California Corporation MTOR Modulators and Uses Thereof
US8618096B2 (en) * 2008-07-21 2013-12-31 The Regents Of The University Of California Prodrug compositions and methods for using the same in treating cancer and malaria
CN104230901A (zh) 2008-09-15 2014-12-24 加利福尼亚大学董事会 用于调节ire1、src和abl活性的方法和组合物
JP2010132587A (ja) * 2008-12-03 2010-06-17 Teika Seiyaku Kk 眼科用剤
US8470997B2 (en) * 2009-02-05 2013-06-25 Gene Signal International Sa Pharmaceutical composition for preventing, stabilising and/or inhibiting blood and lymph vascularization
US8580947B2 (en) 2009-02-05 2013-11-12 Gene Signal International Sa Pharmaceutical composition for preventing, stabilising and/or inhibiting blood and lymph vascularization
RU2482851C2 (ru) * 2009-02-20 2013-05-27 Микро Лабс Лимитед Хранение стабильного продукта простагландина
MX353747B (es) 2009-08-17 2018-01-26 Memorial Sloan Kettering Cancer Center Star Compuesto de union a proteina de choque termico, composiciones, y metodos para producir y usar los mismos.
JP5699149B2 (ja) 2009-09-04 2015-04-08 バイオジェン・アイデック・エムエイ・インコーポレイテッド Ｂｒｕｔｏｎ型チロシンキナーゼ阻害薬
WO2011029043A1 (fr) 2009-09-04 2011-03-10 Biogen Idec Ma Inc. Inhibiteurs hétéroaryles de btk
US8679511B2 (en) * 2009-10-01 2014-03-25 Duquesne University of the Holy Spririt In-situ gel ophthalmic drug delivery system of estradiol or other estrogen for prevention of cataracts
EP2485731B1 (fr) 2009-10-06 2016-05-11 Millennium Pharmaceuticals, Inc. Composes heterocycliques utilises comme inhibiteurs de pdk1
US8980899B2 (en) 2009-10-16 2015-03-17 The Regents Of The University Of California Methods of inhibiting Ire1
PT2493465E (pt) 2009-10-26 2014-12-22 Sephoris Pharmaceuticals Llc Tratamento de queimaduras solares usando analgésicos e anti-histamínicos
US20130035325A1 (en) 2009-11-16 2013-02-07 The Regents Of The University Of California Kinase inhibitors
ME02194B (me) 2009-12-10 2016-02-20 Univ California Agensi koji vežu amiloid
US9522153B2 (en) 2009-12-22 2016-12-20 Allergan, Inc. Compositions and methods for lowering intraocular pressure
DE102010009475B4 (de) 2010-02-26 2011-11-24 F. Holzer Gmbh Verfahren zur Herstellung eines dosierbaren applikationsfertigen Präparates
KR101955691B1 (ko) 2010-03-30 2019-03-07 베르선 코포레이션 트롬빈 억제제로서의 다중치환된 방향족 화합물
KR20130092957A (ko) 2010-04-07 2013-08-21 알러간, 인코포레이티드 안과용 처방용 보존제 조성물의 조합
JP2013523828A (ja) 2010-04-07 2013-06-17 アラーガン インコーポレイテッド 眼科用組成物のための保存剤の組み合わせ
JP5713791B2 (ja) * 2010-05-12 2015-05-07 テイカ製薬株式会社 眼科用剤
KR20130100273A (ko) 2010-08-27 2013-09-10 와카모토 세이야꾸 가부시끼가이샤 점안용 수성 조성물
US8530449B2 (en) 2010-09-09 2013-09-10 Assad S. Sawaya Composition for a topical ophthalmic clear colloidal liquid which undergoes a liquid-gel phase transition in the eye
SG10201507554RA (en) 2010-09-13 2015-10-29 Bev Rx Inc Aqueous drug delivery system comprising off - flavor masking agent
US9273028B2 (en) 2010-10-29 2016-03-01 Biogen Ma Inc. Heterocyclic tyrosine kinase inhibitors
KR101935068B1 (ko) 2011-02-14 2019-01-03 알러간, 인코포레이티드 비마토프로스트 조성물의 에스테르 유도체 및 방법
US9580427B2 (en) 2011-05-17 2017-02-28 The Regents Of The University Of California Kinase inhibitors
US9376438B2 (en) 2011-05-17 2016-06-28 Principia Biopharma, Inc. Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors
SI2710005T1 (sl) 2011-05-17 2017-03-31 Principia Biopharma Inc. Zaviralci tirozinske kinaze
US20140221282A1 (en) 2011-05-25 2014-08-07 Astrazeneca Pharmaceuticals Lp Long duration dual hormone conjugates
JP6109165B2 (ja) 2011-07-01 2017-04-05 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア ヘルペスウイルスワクチンおよび使用方法
AU2012341028C1 (en) 2011-09-02 2017-10-19 Mount Sinai School Of Medicine Substituted pyrazolo[3,4-D]pyrimidines and uses thereof
EP2771341A4 (fr) 2011-10-28 2015-09-23 Univ Texas Nouvelles compositions et procédés pour traiter le cancer
US20150087628A1 (en) 2012-04-10 2015-03-26 The Regents Of The University Of California Compositions and methods for treating cancer
AR091273A1 (es) 2012-06-08 2015-01-21 Biogen Idec Inc Inhibidores de pirimidinil tirosina quinasa
US9353087B2 (en) 2012-06-08 2016-05-31 Biogen Ma Inc. Inhibitors of Bruton's tyrosine kinase
CA2913736A1 (fr) 2012-06-11 2013-12-19 The Regents Of The University Of California Composes et procedes de traitement du cancer
TR201900863T4 (tr) 2012-08-27 2019-02-21 Allergan Inc Beta-klorosiklopentanların hidrofilik ester ön ilaçlarının kullanılmasıyla merkezi korneal kalınlaşmanın azaltılması.
US9090595B2 (en) 2012-08-27 2015-07-28 Allergan, Inc. Reduced central corneal thickening by use of hydrophilic ester prodrugs of beta-chlorocyclopentanes
DK3181567T3 (da) 2012-09-10 2019-06-11 Principia Biopharma Inc Pyrazolopyrimidinforbindelser som kinasehæmmere
WO2014052669A1 (fr) 2012-09-26 2014-04-03 The Regents Of The University Of California Modulation de ire1
EP2909214B1 (fr) 2012-10-22 2020-07-22 City of Hope Dérivés d'étoposide
US9364462B2 (en) 2012-10-30 2016-06-14 The Regents Of The University Of California Alpha-1-adrenergic receptor agonist therapy
EP2953950B1 (fr) 2013-02-11 2021-01-13 The Regents of The University of California Compositions et méthodes de traitement de maladies neurodégénératives
US9321745B2 (en) 2013-03-12 2016-04-26 Allergan, Inc. Inhibition of neovascularization by inhibition of prostanoid IP receptors
US9295665B2 (en) 2013-03-12 2016-03-29 Allergan, Inc. Inhibition of neovascularization by simultaneous inhibition of prostanoid IP and EP4 receptors
EP2968296B1 (fr) 2013-03-12 2020-09-02 The Regents of the University of California Modulateurs de gamma-secrétase
EP2968270A4 (fr) 2013-03-14 2016-08-17 Univ California Modulation de canaux k2p
EP3851109A1 (fr) 2013-03-14 2021-07-21 The Regents of the University of California Agents mucolytiques thiosaccharidiques
CN105283456B (zh) 2013-03-14 2018-12-18 希望之城 5-溴-靛玉红
WO2014146111A2 (fr) 2013-03-15 2014-09-18 The Regents Of The University Of California Composés antalgiques et leurs méthodes d'utilisation
RU2019101889A (ru) 2013-03-15 2019-03-28 Версеон Корпорейшн Полизамещенные ароматические соединения в качестве ингибиторов сериновых протеаз
US9227978B2 (en) 2013-03-15 2016-01-05 Araxes Pharma Llc Covalent inhibitors of Kras G12C
RS57796B1 (sr) 2013-03-15 2018-12-31 Univ California Diestri acikličnog nukleozid fosfonata
CN105209440B (zh) 2013-03-15 2019-07-23 维颂公司 作为凝血酶抑制剂的卤代吡唑
JP6806562B2 (ja) 2013-03-15 2021-01-06 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア ｅＩＦ２α経路の調節因子
AU2014233436B2 (en) 2013-03-15 2019-12-05 Atyr Pharma, Inc. Histidyl-tRNA synthetase-Fc conjugates
RU2015134772A (ru) 2013-03-15 2017-04-21 Аллерган, Инк. Применение биматопроста для повышения выработки лептина
US8957080B2 (en) 2013-04-09 2015-02-17 Principia Biopharma Inc. Tyrosine kinase inhibitors
EP2999472B1 (fr) 2013-05-22 2020-07-22 The Regents of The University of California Inhibiteurs d'aurora kinase
US9795691B2 (en) 2013-06-24 2017-10-24 City Of Hope Chemically-linked nanoparticles
EP3022207A4 (fr) 2013-07-15 2016-12-07 Univ Texas Composés et méthodes pour le traitement du cancer, des troubles neurologiques, du sevrage de l'éthanol, de l'anxiété, de la dépression, et de la douleur neuropathique
EP3636264A1 (fr) 2013-08-19 2020-04-15 The Regents of the University of California Composés et procédés pour traiter un trouble épileptique
WO2015026935A2 (fr) 2013-08-20 2015-02-26 City Of Hope Inhibiteurs de l'hdac8 pour le traitement du cancer
WO2015031799A1 (fr) 2013-08-30 2015-03-05 The Regents Of The University Of California, A California Corporation Compositions contenant des nanocristaux scintillateurs et leurs procédés d'utilisation
TWI659021B (zh) 2013-10-10 2019-05-11 亞瑞克西斯製藥公司 Ｋｒａｓ ｇ１２ｃ之抑制劑
SI3080103T1 (sl) 2013-12-11 2018-11-30 Biogen Ma Inc. Biarilne spojine, ki so uporabne za zdravljenje človeških bolezni na področju onkologije, nevrologije in imunologije
US10280169B2 (en) 2013-12-11 2019-05-07 Biogen Ma Inc. Biaryl bruton's tyrosine kinase inhibitors
RU2016128528A (ru) 2013-12-23 2018-01-30 Мемориал Слоун-Кеттеринг Кэнсэ Сентр Способы и реактивы для введения радиоактивной метки
JP2017502089A (ja) 2014-01-10 2017-01-19 マニスティー パートナーズ エルエルシーＭａｎｉｓｔｅｅ Ｐａｒｔｎｅｒｓ Ｌｌｃ 偏頭痛の処置
WO2015116856A2 (fr) 2014-01-29 2015-08-06 City Of Hope Antagonistes du récepteur x de farnésoïde
WO2015123365A1 (fr) 2014-02-11 2015-08-20 Mitokinin Llc Compositions et procedes les utilisant pour le traitement de maladie neurodegenerative et mitochondriale
JP6889433B2 (ja) 2014-02-14 2021-06-18 ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア 薬剤の選択的送達のためのプロドラッグとしての環状ペルオキシド
KR20160124835A (ko) 2014-02-20 2016-10-28 알러간, 인코포레이티드 베타-클로로시클로펜탄의 친수성 에스테르 프로드럭의 사용에 의해 감소된 중앙 각막 비후
CN112353806A (zh) 2014-02-21 2021-02-12 普林斯匹亚生物制药公司 Btk抑制剂的盐和固体形式
US20150259288A1 (en) 2014-03-14 2015-09-17 City Of Hope 5-bromo-indirubins
AU2015235929B2 (en) 2014-03-26 2019-02-14 City Of Hope Treatment of BRCA1-defective cancer or resistant cancers
ES2908240T3 (es) 2014-04-07 2022-04-28 Univ California Inhibidores de la enzima amida hidrolasa de ácidos grasos (FAAH) con biodisponibilidad oral mejorada y su uso como medicamentos
WO2015175707A1 (fr) 2014-05-13 2015-11-19 Memorial Sloan Kettering Cancer Center Modulateurs de hsp70 et leur procédés de fabrication et leur utilisation
WO2015183794A1 (fr) 2014-05-27 2015-12-03 City Of Hope Complexes d'agonistes de tgr5 pour le traitement du diabète et du cancer
US9012402B1 (en) 2014-06-11 2015-04-21 James Blanchard Gel for topical delivery of NSAIDs to provide relief of musculoskeletal pain and methods for its preparation
WO2016004383A1 (fr) 2014-07-03 2016-01-07 City Of Hope Antagonistes de ctla-4 ciblant spécifiquement les tumeurs
WO2016018917A2 (fr) 2014-07-28 2016-02-04 The Regents Of The University Of Califoria Compositions et procédés de fabrication d'acides nucléiques polymérisés
WO2016023036A1 (fr) 2014-08-08 2016-02-11 The Regents Of The University Of California Polymères peptidiques à haute densité
JP6692798B2 (ja) 2014-09-11 2020-05-13 ザ・リージエンツ・オブ・ザ・ユニバーシテイ・オブ・カリフオルニア ｍＴＯＲＣ１阻害剤
SG11201701957XA (en) 2014-09-15 2017-04-27 Univ California Nucleotide analogs
CA2960790A1 (fr) 2014-09-17 2016-03-24 Verseon Corporation Composes de pyridone substituee par pyrazolyl en tant qu'inhibiteurs de serine protease
JO3556B1 (ar) 2014-09-18 2020-07-05 Araxes Pharma Llc علاجات مدمجة لمعالجة السرطان
US9862701B2 (en) 2014-09-25 2018-01-09 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
US10011600B2 (en) 2014-09-25 2018-07-03 Araxes Pharma Llc Methods and compositions for inhibition of Ras
AU2015327817B2 (en) 2014-10-02 2020-04-23 Allergan, Inc. Ester prodrugs of gamma-lactams and their use
WO2016061147A1 (fr) 2014-10-13 2016-04-21 John Eric Paderi Revêtement d'une lumière vasculaire en vue d'une fistule artério-veineuse
WO2016061145A1 (fr) 2014-10-13 2016-04-21 Symic Biomedical, Inc. Protéoglycanes synthétiques pour empêcher l'adhérence tissulaire
WO2016065083A1 (fr) 2014-10-21 2016-04-28 Symic Biomedical, Inc. Peptidoglycanes comprenant des peptides se fixant au collagène pour le traitement d'une lésion gastro-œsophagienne
PT3233103T (pt) 2014-12-18 2021-01-18 Principia Biopharma Inc Tratamento de pênfigo
US10689423B2 (en) 2015-01-13 2020-06-23 City Of Hope CTLA4-binding protein peptide-linker masks
EP3244910B1 (fr) 2015-01-16 2020-09-16 City of Hope Anticorps de pénétration cellulaire
US10227333B2 (en) 2015-02-11 2019-03-12 Curtana Pharmaceuticals, Inc. Inhibition of OLIG2 activity
PT3261640T (pt) 2015-02-25 2022-07-06 Univ California Agonistas de 5ht para tratamento de distúrbios de epilepsia
EP3262040A4 (fr) 2015-02-27 2018-09-12 The Regents of The University of California Petites molécules permettant le rajeunissement du cartilage
US10532995B2 (en) 2015-02-27 2020-01-14 Verseon Corporation Substituted pyrazole compounds as serine protease inhibitors
CN107530304A (zh) 2015-02-27 2018-01-02 科泰纳制药公司 Olig2活性的抑制
US10383816B2 (en) 2015-03-02 2019-08-20 Afgin Pharma, Llc Topical regional neuro-affective therapy with cannabinoid combination products
US10716766B2 (en) 2015-03-02 2020-07-21 Afgin Pharma, Llc Topical regional neuro-affective therapy with cannabinoids
JP6976854B2 (ja) 2015-03-30 2021-12-08 シティ・オブ・ホープCity of Hope 機械的にかみ合った複合体
EP3280708B1 (fr) 2015-04-10 2021-09-01 Araxes Pharma LLC Composés quinazolines substitués et procédés pour leur utilisation
MX2017013275A (es) 2015-04-15 2018-01-26 Araxes Pharma Llc Inhibidores triciclicos fusionados de kras y metodos de uso de los mismos.
CA2982890C (fr) 2015-04-17 2023-08-22 Ludwig Institute For Cancer Research Ltd Inhibiteurs de plk4
CA2983293C (fr) 2015-04-24 2023-06-20 The Regents Of The University Of California Modulateurs de la liaison ror1-ror2
PT3294764T (pt) 2015-05-15 2021-02-15 Hope City Composições de recetores de antigénios quiméricos
US10787664B2 (en) 2015-05-26 2020-09-29 City Of Hope Compounds of chemically modified oligonucleotides and methods of use thereof
US20180282310A1 (en) 2015-06-10 2018-10-04 Biogen Ma Inc. Forms and compositions of biaryl inhibitors of bruton's tyrosine kinase
US10765696B2 (en) 2015-06-10 2020-09-08 City Of Hope Compositions of and methods of treatment with zwitterionic polysaccharide
TW201718572A (zh) 2015-06-24 2017-06-01 普林斯匹亞生物製藥公司 酪胺酸激酶抑制劑
CN114224907A (zh) 2015-07-02 2022-03-25 希望之城 包括硫代磷酸化寡脱氧核苷酸的化合物和组合物及其使用方法
US10144724B2 (en) 2015-07-22 2018-12-04 Araxes Pharma Llc Substituted quinazoline compounds and methods of use thereof
CN108135958B (zh) 2015-08-06 2022-03-04 希望之城 细胞穿透蛋白-抗体缀合物及其使用方法
EP3128007A1 (fr) 2015-08-07 2017-02-08 Gene Signal International SA Émulsion stérile comprenant un oligonucléotide de phosphorothioate stable
US11136301B2 (en) 2015-08-31 2021-10-05 The Regents of the University of California, A California Corporation et al. Broad spectrum antiviral compounds and uses thereof
US11124483B2 (en) 2015-09-02 2021-09-21 The Regents Of The University Of California HER3 ligands and uses thereof
CN108349900A (zh) 2015-09-04 2018-07-31 希望之城 雄激素受体拮抗剂
CN108430978B (zh) 2015-09-25 2022-11-22 路德维格癌症研究所有限责任公司 3-羟基-喹唑啉-2,4-二酮衍生物及其作为核酸酶调节剂的用途
WO2017058768A1 (fr) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibiteurs de protéines kras portant la mutation g12c
EP3356359B1 (fr) 2015-09-28 2021-10-20 Araxes Pharma LLC Inhibiteurs de protéines kras portant la mutation g12c
US10858343B2 (en) 2015-09-28 2020-12-08 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
WO2017058902A1 (fr) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibiteurs de protéines mutantes kras g12c
WO2017058915A1 (fr) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibiteurs de protéines mutantes kras g12c
WO2017058805A1 (fr) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibiteurs de protéines kras portant la mutation g12c
US10875842B2 (en) 2015-09-28 2020-12-29 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
TW201718028A (zh) 2015-10-13 2017-06-01 賽米克Ｉｐ有限責任公司 Ve-鈣黏蛋白結合性生物結合物
US10801026B2 (en) 2015-10-15 2020-10-13 City Of Hope Compounds and compositions including phosphorothioated oligodeoxynucleotide, and methods of use thereof
WO2017070256A2 (fr) 2015-10-19 2017-04-27 Araxes Pharma Llc Méthode de criblage d'inhibiteurs de ras
EP3364956A4 (fr) 2015-10-23 2019-05-01 ERX Pharmaceuticals, Inc. Analogues de célastrol
KR20180101329A (ko) 2015-10-23 2018-09-12 선에시스 파마슈티컬스 인코포레이티드 암 치료에 사용하기 위한 헤테로시클릭 pdk1 억제제
US11058700B2 (en) 2015-10-28 2021-07-13 City Of Hope Macrocyclic lactones and uses thereof as modulators of purinergic receptors
CA3005089A1 (fr) 2015-11-16 2017-05-26 Araxes Pharma Llc Composes quinazoline substitues en position 2 comprenant un groupe heterocyclique substitue et leur methode d'utilisation
WO2017100546A1 (fr) 2015-12-09 2017-06-15 Araxes Pharma Llc Procédés de préparation de dérivés de quinazoléine
EP3386549A4 (fr) 2015-12-10 2019-08-07 City of Hope Anticorps couplés à la cyanine à pénétration cellulaire
PT3394040T (pt) 2015-12-24 2022-03-24 Univ California Reguladores de cftr e seus métodos de uso
EP3394046B1 (fr) 2015-12-24 2022-03-09 The Regents Of The University Of California Régulateurs cftr et méthodes pour les utiliser
CN108697690B (zh) 2016-01-05 2022-01-14 加利福尼亚大学董事会 苯并噻唑两亲物
US10519442B2 (en) 2016-02-11 2019-12-31 City Of Hope Twist signaling inhibitor compositions and methods of using the same
BR112018068798A2 (pt) 2016-03-17 2019-01-22 Univ California composições e métodos para tratamento de doenças parasíticas
WO2017172979A1 (fr) 2016-03-30 2017-10-05 Araxes Pharma Llc Composés quinazoline substitués et procédés d'utilisation
GR1009006B (el) 2016-04-01 2017-04-04 Φαρματεν Ανωνυμος Βιομηχανικη Και Εμπορικη Εταιρεια Φαρμακευτικων Ιατρικων Και Καλλυντικων Προϊοντων Φαρμακευτικο σκευασμα ελευθερο συντηρητικου για οφθαλμικη χρηση περιεχον βιματοπροστη και τιμολολη
GR1009040B (el) 2016-04-19 2017-05-19 Φαρματεν Ανωνυμος Βιομηχανικη Και Εμπορικη Εταιρεια Φαρμακευτικων Ιατρικων Και Καλλυντικων Προϊοντων Φαρμακευτικο οφθαλμικο σκευασμα ελευθερο συντηρητικου
ES2886935T3 (es) 2016-04-25 2021-12-21 Forma Therapeutics Inc Inhibidores de FASN para su uso en el tratamiento de esteatohepatitis no alcohólica
AU2017257151A1 (en) 2016-04-29 2018-11-15 Board Of Regents, The University Of Texas System Sigma receptor binders
TW201808914A (zh) 2016-05-05 2018-03-16 嘉來克生命科學有限責任公司 整合應激途徑之調節劑
TWI763668B (zh) 2016-05-05 2022-05-11 美商嘉來克生命科學有限責任公司 整合應激途徑之調節劑
TN2018000351A1 (en) 2016-05-12 2020-06-15 Anacor Pharmaceuticals Inc Oxaborole esters and uses thereof
CA3063834A1 (fr) 2016-05-26 2017-11-30 The Regents Of The University Of California Associations de modulateurs du recepteur des oestrogenes
CA3028169A1 (fr) 2016-06-29 2018-01-04 Principia Biopharma Inc. Formulations a liberation modifiee a base de 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidine-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetane-3-yl)piperazin e-1-yl]pent-2-enenitrile
WO2018013609A2 (fr) 2016-07-11 2018-01-18 The Regents The University Of California Nanoparticules synthétiques de mélanine et leurs utilisations
US10646488B2 (en) 2016-07-13 2020-05-12 Araxes Pharma Llc Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
SG11201900515PA (en) 2016-07-21 2019-02-27 Biogen Ma Inc Succinate forms and compositions of bruton's tyrosine kinase inhibitors
JP6985388B2 (ja) 2016-07-29 2021-12-22 ラプト・セラピューティクス・インコーポレイテッド ケモカイン受容体調節剤及びそれの使用
US20180049994A1 (en) 2016-08-16 2018-02-22 Afgin Pharma, Llc Topical regional neuro-affective therapy with caryophyllene
US11254667B2 (en) 2016-08-17 2022-02-22 Children's Hospital Medical Center Substituted imidazo[1,2-A]pyridines as IRAK 1/4 and flt3 inhibitors
US11542261B2 (en) 2016-08-17 2023-01-03 Children's Hospital Medical Center Substituted Imidazo[1,2-a]-pyridines as IRAK 1/4 and FLT3 inhibitors
WO2018039612A1 (fr) 2016-08-26 2018-03-01 The Regents Of The University Of California Compositions et méthodes favorisant la croissance des cheveux au moyen d'inhibiteurs de mpc1
CN109982710A (zh) 2016-09-13 2019-07-05 杰克逊实验室 靶向增强的dna去甲基化
JP7088912B2 (ja) 2016-09-15 2022-06-21 シティ・オブ・ホープ ジチオｅｔｐ誘導体
US10849955B2 (en) 2016-09-28 2020-12-01 City Of Hope Methods of treating pancreatic cancer using GPCR antagonists
WO2018064510A1 (fr) 2016-09-29 2018-04-05 Araxes Pharma Llc Inhibiteurs de protéines mutantes kras g12c
US10377743B2 (en) 2016-10-07 2019-08-13 Araxes Pharma Llc Inhibitors of RAS and methods of use thereof
US10646540B2 (en) 2016-11-18 2020-05-12 City Of Hope Peptide inhibitors of twist
MX2019007030A (es) 2016-12-15 2020-01-15 Univ California Composiciones y metodos para el tratamiento del cancer.
EP3573967A1 (fr) 2017-01-26 2019-12-04 Araxes Pharma LLC Composés hétéro-hétéro-bicycliques fusionnés et leurs procédés d'utilisation
EP3573970A1 (fr) 2017-01-26 2019-12-04 Araxes Pharma LLC Dérivés de 1-(6-(3-hydroxynaphtalen-1-yl)quinazolin-2-yl)azétidin-1-yl)prop-2-en-1-one et composés similaires utilisés en tant qu'inhibiteurs de kras g12c pour le traitement du cancer
US11274093B2 (en) 2017-01-26 2022-03-15 Araxes Pharma Llc Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
US11358959B2 (en) 2017-01-26 2022-06-14 Araxes Pharma Llc Benzothiophene and benzothiazole compounds and methods of use thereof
US11279689B2 (en) 2017-01-26 2022-03-22 Araxes Pharma Llc 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1 yl)prop-2-en-1-one derivatives and similar compounds as KRAS G12C modulators for treating cancer
AU2018214221B2 (en) 2017-02-03 2024-02-01 Laboratoires Kôl Sterile formulation comprising a stable phosphorothioate oligonucleotide
US10052343B1 (en) 2017-02-03 2018-08-21 Gene Signal International Sa Sterile formulation comprising a stable phosphorothioate oligonucleotide
JP2020521741A (ja) 2017-05-25 2020-07-27 アラクセス ファーマ エルエルシー がんの処置のための化合物およびその使用の方法
BR112019024674A2 (pt) 2017-05-25 2020-06-16 Araxes Pharma Llc Inibidores covalentes da kras
US11639346B2 (en) 2017-05-25 2023-05-02 Araxes Pharma Llc Quinazoline derivatives as modulators of mutant KRAS, HRAS or NRAS
CA3067695A1 (fr) 2017-06-21 2018-12-27 Mitokinin, Inc. Compositions et methodes les utilisant pour le traitement d'une maladie neurodegenerative et mitochondriale
WO2019006371A1 (fr) 2017-06-30 2019-01-03 City Of Hope Compositions et procédés de modulation de l'activité macrophage
US10821075B1 (en) 2017-07-12 2020-11-03 James Blanchard Compositions for topical application of a medicaments onto a mammalian body surface
US11389460B2 (en) 2017-09-15 2022-07-19 City Of Hope Methods and compositions for treating endometrial cancer
US20200354452A1 (en) 2017-09-29 2020-11-12 City Of Hope Cars and bispecific antibodies for treatment of mantle cell lymphoma
CN111386283A (zh) 2017-09-29 2020-07-07 基因泰克公司 肽抗菌复合物及其使用方法
WO2019070917A1 (fr) 2017-10-03 2019-04-11 The Schepens Eye Research Institute, Inc. Composés et compositions pour inhiber la dégénérescence de l'épithélium pigmentaire rétinien et procédés les utilisant
RU2020115154A (ru) 2017-10-10 2021-11-15 Сирос Фармасьютикалз, Инк. Производные пирролотриазина и способы ингибирования киназ там
US11618780B2 (en) 2017-10-20 2023-04-04 City Of Hope Composition and method for activating latent human immunodeficiency virus (HIV)
BR112020008836A2 (pt) 2017-11-02 2021-03-30 Calico Life Sciences Llc Moduladores da via de estresse integrada
CA3080959A1 (fr) 2017-11-02 2019-05-09 Calico Life Sciences Llc Modulateurs de la voie de reponse integree au stress
CA3080808A1 (fr) 2017-11-02 2019-05-09 Calico Life Sciences Llc Modulateurs de la voie de reponse integree au stress
UY37958A (es) 2017-11-02 2019-05-31 Abbvie Inc Moduladores de la vía de estrés integrada
UY37957A (es) 2017-11-02 2019-05-31 Abbvie Inc Moduladores de la vía de estrés integrada
BR112020008834A2 (pt) 2017-11-02 2020-12-22 Calico Life Sciences Llc Moduladores da via de estresse integrada
MX2020004519A (es) 2017-11-02 2020-11-09 Calico Life Sciences Llc Moduladores de la vía de estrés integrada.
JP7335241B2 (ja) 2017-11-02 2023-08-29 カリコ ライフ サイエンシーズ エルエルシー 統合的ストレス経路の調節剤
UY37956A (es) 2017-11-02 2019-05-31 Abbvie Inc Moduladores de la vía de estrés integrada
AU2018360766A1 (en) 2017-11-06 2020-05-21 Rapt Therapeutics, Inc. Anticancer agents
WO2019113542A1 (fr) 2017-12-07 2019-06-13 Amplyx Pharmaceuticals, Inc. Agents antifongiques dérivés de pyridine substitués par un hétérocycle
WO2019126037A1 (fr) 2017-12-19 2019-06-27 City Of Hope Arncr transactivateurs et arng modifiés et leurs utilisations
CA3088529A1 (fr) 2018-01-16 2019-07-25 Syros Pharmaceuticals, Inc. Inhibiteurs de la kinase cycline-dependante 7 (cdk7)
EP3740207A4 (fr) 2018-01-16 2021-10-13 Syros Pharmaceuticals, Inc. Inhibiteurs de la kinase cycline-dépendante 7 (cdk7)
JP7355758B2 (ja) 2018-01-26 2023-10-03 ラプト・セラピューティクス・インコーポレイテッド ケモカイン受容体調節剤及びその使用
KR20200143376A (ko) 2018-03-13 2020-12-23 샤이어 휴먼 지네틱 테라피즈 인크. 혈장 칼리크레인 억제제로서의 치환된 이미다조피리딘 및 이의 용도
EP3784233B1 (fr) 2018-04-27 2024-06-05 Spruce Biosciences, Inc. Méthodes de traitement de tumeurs des vertiges surrénaliens des testicules et des ovaires
EP3788050A1 (fr) 2018-05-01 2021-03-10 Revolution Medicines, Inc. Analogues de rapamycine liés à c26 utilisés en tant qu'inhibiteurs de mtor
IL300091A (en) 2018-05-01 2023-03-01 Revolution Medicines Inc C40-, C28-, and C-32-linked rapamycin analogs as MTOR inhibitors
WO2019213611A1 (fr) 2018-05-04 2019-11-07 Cirius Therapeutics, Inc. Analogues de thiazolidinedione pour le traitement de nafld et de maladies métaboliques
JP2021527051A (ja) 2018-06-05 2021-10-11 ラプト・セラピューティクス・インコーポレイテッド ピラゾロ−ピリミジン−アミノ−シクロアルキル化合物及びその治療的使用
MX2020014223A (es) 2018-06-21 2021-06-23 Calico Life Sciences Llc Inhibidores de proteina tirosina fosfatasa y sus metodos de uso.
CA3104653A1 (fr) 2018-06-25 2020-01-02 Amplyx Pharmaceuticals, Inc. Derives de pyridine substitues par un noyau heterocyclique et un groupe amino
CN112867503A (zh) 2018-08-24 2021-05-28 希望之城 掩蔽的细胞因子缀合物
TWI771621B (zh) 2018-10-11 2022-07-21 美商嘉來克生命科學有限責任公司 整合應激路徑之前藥調節劑
SG11202103694UA (en) 2018-11-01 2021-05-28 Lynk Pharmaceuticals Co Ltd Tricyclic janus kinase 1 inhibitors, and compositions and methods thereof
US20220008336A1 (en) * 2018-11-26 2022-01-13 Aiviva Biopharma, Inc. Pharmaceutical biodissolvable gels for drug delivery
TW202100515A (zh) 2019-03-14 2021-01-01 美商嘉來克生命科學有限責任公司 蛋白酪胺酸磷酸酶抑制劑及其使用方法
SG11202111918PA (en) 2019-04-30 2021-11-29 Calico Life Sciences Llc Substituted cycloalkyls as modulators of the integrated stress pathway
FR3095592B1 (fr) * 2019-05-02 2021-05-21 Unither Pharmaceuticals Composition à base de gomme gellane et de phényléphrine, procédé de fabrication et utilisation comme produit ophtalmique
CA3140046A1 (fr) 2019-05-15 2020-11-19 Bexson Biomedical, Inc. Formulation de ketamine pour injection sous-cutanee
US11370803B2 (en) 2019-09-18 2022-06-28 Takeda Pharmaceutical Company Limited Heteroaryl plasma kallikrein inhibitors
US20220348632A1 (en) 2019-09-18 2022-11-03 Novartis Ag Nkg2d fusion proteins and uses thereof
JP2022548696A (ja) 2019-09-18 2022-11-21 武田薬品工業株式会社 血漿カリクレインインヒビター及びその使用
CA3158521A1 (fr) 2019-11-13 2021-05-20 Rapt Therapeutics, Inc. Formes cristallines d'un antagoniste du recepteur de chimiokine c-c de type 4 et leurs utilisations
EP4077291A1 (fr) 2019-12-18 2022-10-26 Calico Life Sciences LLC Inhibiteurs de protéine tyrosine phosphatase et leurs méthodes d'utilisation
US20230143595A1 (en) 2020-03-31 2023-05-11 Sentiss Pharma Private Limited A sterilization process of timolol gel forming solution through aseptic filtration
GR1010024B (el) 2020-05-06 2021-06-01 Φαρματεν Α.Β.Ε.Ε. Φαρμακευτικο σκευασμα ελευθερο συντηρητικου για οφθαλμικη χορηγηση που περιλαμβανει βριμονιδινη
EP4153564A4 (fr) 2020-05-19 2024-06-19 Cybin IRL Limited Dérivés de tryptamine deutérés et procédés d'utilisation
AU2021327136A1 (en) 2020-08-18 2023-02-16 Cybin Irl Limited Therapeutic phenethylamine compositions and methods of use
KR20230129384A (ko) 2020-11-02 2023-09-08 트레테라 코퍼레이션 데옥시시티딘 키나제 억제제의 결정형 및 이의 용도
EP4247340A1 (fr) 2020-11-18 2023-09-27 Bexson Biomedical, Inc. Formulations salines de composés pharmaceutiques à base d'agents complexants
WO2022133237A2 (fr) 2020-12-18 2022-06-23 Cornell University Méthodes de traitement de troubles neurodégénératifs et de cancers liés à stat3 au moyen de suppresseurs de fuite d'électrons
US11918582B2 (en) 2021-03-15 2024-03-05 Rapt Therapeutics, Inc. Pyrazole pyrimidine compounds and uses thereof
WO2022197763A1 (fr) 2021-03-17 2022-09-22 Shire Human Genetic Therapies, Inc. Inhibiteurs de la kallicréine plasmatique
CA3208243A1 (fr) 2021-03-17 2022-09-22 Nikolaos PAPAIOANNOU Inhibiteurs heteroaryle de la kallicreine plasmatique
JP2024510502A (ja) 2021-03-17 2024-03-07 武田薬品工業株式会社 血漿カリクレインのイミダゾピリジニル阻害剤
CN117355523A (zh) 2021-03-17 2024-01-05 武田药品工业株式会社 血浆激肽释放酶的多环抑制剂
WO2022197756A1 (fr) 2021-03-17 2022-09-22 Shire Human Genetic Therapies, Inc. Inhibiteurs de la kallicréine plasmatique
WO2023156450A1 (fr) 2022-02-15 2023-08-24 Cybin Irl Limited Compositions de phénéthylamine thérapeutique et procédés d'utilisation
WO2023156453A1 (fr) 2022-02-15 2023-08-24 Cybin Irl Limited Dérivés de phénétylamine, compositions et procédés d'utilisation
US20230322741A1 (en) 2022-04-06 2023-10-12 Rapt Therapeutics, Inc. Chemokine receptor modulators and uses thereof

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2441729A (en) * 1943-12-08 1948-05-18 Kelco Co Algin gel-forming compositions
US2935447A (en) * 1957-02-19 1960-05-03 Kelco Co Appetite depressant containing alginate
FR1312244A (fr) * 1962-01-09 1962-12-14 Bernburg Serum Werk Veb Procédé de fabrication de supports de pommade exempts de corps gras
BE731578A (fr) * 1969-04-16 1969-10-01
AU7776275A (en) * 1974-04-11 1976-08-05 Warner Lambert Co Production of base for topical steroids
US4013792A (en) * 1974-04-11 1977-03-22 Warner-Lambert Company Process for the production of base for topical steroids
NL188266C (nl) * 1975-07-29 1992-05-18 Merck & Co Inc Werkwijze ter bereiding van een oogheelkundig inplantaat.
US4039662A (en) * 1975-12-04 1977-08-02 Alcon Laboratories, Inc. Ophthalmic solution
US4188373A (en) * 1976-02-26 1980-02-12 Cooper Laboratories, Inc. Clear, water-miscible, liquid pharmaceutical vehicles and compositions which gel at body temperature for drug delivery to mucous membranes
CA1072413A (fr) * 1976-07-13 1980-02-26 West Laboratories Systemes de gel de type poloxamer, a temperature de gelification superieure a la temperature ambiante
US4136177A (en) * 1977-01-31 1979-01-23 American Home Products Corp. Xanthan gum therapeutic compositions
US4136173A (en) * 1977-01-31 1979-01-23 American Home Products Corp. Mixed xanthan gum and locust beam gum therapeutic compositions
US4326053A (en) * 1978-12-04 1982-04-20 Merck & Co., Inc. Polysaccharide S-60 and bacterial fermentation process for its preparation
KR830002802B1 (ko) * 1978-12-04 1983-12-16 제임스 에프 · 너우톤 박테리아 발효에 의한 다당류 s-60의 제조방법
US4409205A (en) * 1979-03-05 1983-10-11 Cooper Laboratories, Inc. Ophthalmic solution
US4407792A (en) * 1979-05-09 1983-10-04 Alcon Laboratories, Inc. Sustained release ophthalmic drug dosage
US4474751A (en) * 1983-05-16 1984-10-02 Merck & Co., Inc. Ophthalmic drug delivery system utilizing thermosetting gels
US4503084A (en) * 1983-05-31 1985-03-05 Merck & Co., Inc. Non-heated gellan gum gels
US4563366A (en) * 1983-05-31 1986-01-07 Merck & Co., Inc. Non-heated gellan gum gels
GB8318403D0 (en) * 1983-07-07 1983-08-10 Sutherland I W Gel-forming polysaccharides
DE3335593A1 (de) * 1983-09-30 1985-04-11 Diamalt AG, 8000 München Gelier- und verdickungsmittel auf der basis von cassia-galactomannanen
US4717713A (en) * 1983-10-31 1988-01-05 Research Corporation Controlled release liquid pharmaceutical
US4551456A (en) * 1983-11-14 1985-11-05 Merck & Co., Inc. Ophthalmic use of norfloxacin and related antibiotics
US4517216A (en) * 1984-03-05 1985-05-14 Merck & Co., Inc. Gellan gum/gelatin blends
GB8431699D0 (en) * 1984-12-14 1985-01-30 Mars G B Ltd Gel system

Also Published As

Publication number Publication date
ATE72990T1 (de) 1992-03-15
PT83471A (en) 1986-11-01
DK170500B1 (da) 1995-10-02
HK42594A (en) 1994-05-13
ES2002401A6 (es) 1988-08-01
KR940000229B1 (ko) 1994-01-12
AU6318986A (en) 1987-04-09
FI91217B (fi) 1994-02-28
FR2588189B1 (fr) 1988-12-02
DK469886A (da) 1987-04-04
FI91217C (fi) 1994-06-10
NZ217662A (en) 1990-02-26
CN86106637A (zh) 1987-04-08
PT83471B (pt) 1988-11-30
GR862444B (en) 1987-01-27
CA1280367C (fr) 1991-02-19
NO173212C (no) 1993-11-17
DE3684121D1 (de) 1992-04-09
CY1779A (en) 1995-10-20
IE59464B1 (en) 1994-02-23
LV5725B4 (lv) 1996-06-20
DE227494T1 (de) 1988-03-17
IL80156A (en) 1990-09-17
JPS62181228A (ja) 1987-08-08
EP0227494A1 (fr) 1987-07-01
CN1046094C (zh) 1999-11-03
LV5725A4 (lv) 1996-02-20
AU595240B2 (en) 1990-03-29
EP0227494B1 (fr) 1992-03-04
US4861760A (en) 1989-08-29
LU88694I2 (fr) 1996-04-29
DK469886D0 (da) 1986-10-02
NO863916L (no) 1987-04-06
FI863990A (fi) 1987-04-04
NL950012I1 (nl) 1996-10-01
IL80156A0 (en) 1986-12-31
NO173212B (no) 1993-08-09
NO1995003I1 (no) 1995-04-10
FR2588189A1 (fr) 1987-04-10
NO863916D0 (no) 1986-10-02
IE862481L (en) 1987-04-03
FI863990A0 (fi) 1986-10-02
JPH0667853B2 (ja) 1994-08-31
KR870003773A (ko) 1987-05-04

Similar Documents

Publication Publication Date Title
CY1779A (en) Pharmaceutical composition of the type which undergoes liquid-gel phase transition
IL74804A0 (en) Human physiologically active polypeptide,its production and pharmaceutical compositions containing it
NZ218948A (en) Pharmaceutical preparations containing viscous gels for administration by syringe
ES8601706A1 (es) Una composicion farmaceutica
GB2007091A (en) Ophthalmic composition
DE3772521D1 (de) Insulinzubereitung fuer nicht-parenterale verabreichung.
ES8800055A1 (es) Procedimiento para la preparacion de una composicion que contiene una sal de acido hialuronico.
IT8447957A1 (it) Composizione per rigenerare il collegamento del tessuto connettivo della pella, e suo procedimento di preparazione.
IL89276A0 (en) Human relaxin formulation
ZA87472B (en) System for delivering drug with enhanced bioacceptability
KR900015768A (ko) 고형겔 외용약 전달 시스템
EP0208313A3 (fr) Agent gélifiant
KR870000015A (ko) 쑥차의 제조방법
KR960015400B1 (en) Method of production for the extemporary preparation of cosmetic gel or cream
KR900702018A (ko) 단백질과 핵산
ATE47518T1 (de) Injizierbare pharmazeutische zusammenstellungen die bestaendige 5-adenosyl-l-methionin-salze enthalten.
IT1214915B (it) Derivato dell'acido 4-metossiisoftalico con attivita'farmacologica in disordini tromboembolici e procedimento per la sua preparazione
IT8720271A0 (it) Nuovi derivati dell'ergolene, composizioni farmaceutiche che licontengono e procedimento per lapreparazione dei medesimi.
ES2033927T3 (es) Utilizacion de la forma farmaceutica de "gel" conteniendo acido n-(2,6-cicloro-m-tolil)-antranilico (acido meclofenamico) utilizable en terapia de uso topico.
ES2009930A6 (es) Mejoras en la patente de invencion 537.819 por procedimiento para anchoar.
PH23149A (en) Hyaluronic acid fractions having pharmaceutical activity,pharmaceutical compositions containing the same and method of use thereof